Acadian Asset's 15-min chart triggers KDJ Death Cross, Bearish Marubozu signal.

Acadian Asset's 15-minute chart has triggered a KDJ Death Cross, coupled with a bearish Marubozu candlestick pattern at 09/22/2025 14:15. This technical indicator suggests that the momentum of the stock price is shifting towards the downside, potentially leading to further decreases. The sellers are currently in control of the market, and it is likely that the bearish momentum will persist.

Acadian Asset Management LLC recently reduced its stake in Nkarta Inc. (NASDAQ: NKTX) by 25.9% in the first quarter of 2025, according to its latest filing with the Securities and Exchange Commission (SEC). The firm owned 629,378 shares after selling 220,423 shares during the quarter, representing approximately 0.89% of Nkarta's stock worth $1,156,000 at the end of the reporting period Acadian Asset Management LLC Has $1.16 Million Stock Holdings in Nkarta, Inc. $NKTX^[1].

Nkarta's stock price has been volatile, trading at $1.99 with a 1-year low of $1.31 and a high of $5.68. Analysts maintain a consensus rating of "Buy" with a target price of $13.60. Despite the recent reduction in Acadian's stake, several other institutional investors have increased their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position valued at approximately $32,000, while Bank of America Corp DE, Deutsche Bank AG, Wellington Management Group LLP, and Nuveen Asset Management LLC all boosted their stakes in the fourth quarter of 2024 Acadian Asset Management LLC Has $1.16 Million Stock Holdings in Nkarta, Inc. $NKTX^[1].

Technical indicators suggest a potential bearish trend for Nkarta. On September 22, 2025, at 14:15, Acadian's 15-minute chart triggered a KDJ Death Cross, coupled with a bearish Marubozu candlestick pattern. This technical indicator suggests that the momentum of the stock price is shifting towards the downside, potentially leading to further decreases. The sellers are currently in control of the market, and it is likely that the bearish momentum will persist .

Nkarta's recent earnings report on August 12, 2025, showed earnings per share (EPS) of $0.31, beating analysts' consensus estimates by $0.06. However, analysts forecast that Nkarta will post -1.7 EPS for the current year. The company's lead product candidate, NKX019, is in Phase 1 clinical trials for treating relapsed/refractory non-hodgkin lymphoma and lupus nephritis Acadian Asset Management LLC Has $1.16 Million Stock Holdings in Nkarta, Inc. $NKTX^[1].